Study of Ceritinib for Cancer Patients whose tumors have ALK or ROS1 mutations

What we are studying

Researchers want to know if Ceritinib is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies. Ceritinib is called a “targeted” drug. This means it targets particular processes in your cancer which are not working properly in cancer cells in your body, which we think causes your disease.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Adults diagnosed with a solid tumor or blood cancer that has been identified as having an ALK or ROS1 change
  • Must have received at least one prior treatment for their disease
  • Must have progressive disease and in need of treatment

What is involved

  • Genetic testing once for study entry
  • Physical exams every month
  • Blood testing every 2 weeks for the first month and then every month
  • Electrocardiogram (ECG) every month
  • Echocardiogram
  • CT scans or MRI every 8 weeks
  • Depending on solid tumor may also have: CA-125 and/or PSA every 8 weeks; Lymphoma patients will have PET Scan
  • Bone marrow and SPEP every 8 weeks; Multiple Myeloma will also have Bone Marrow
  • Leukemia patients will have additional labs at each visit and Bone Marrow

Compensation

None

Contact Information

Study Coordinator
Scarlett Hutchens, RN, BSN
Email
snhutche@wakehealth.edu
Phone
336-713-6915
Principal Investigator
Glenn Lesser, MD

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.